Introduction
============

The incidence of breast cancer (BC) is extremely high, and malignant lymphoma (ML) is a common malignant disease. It is also well known that BC is the most frequent secondary malignancy following treatment for Hodgkin's lymphoma (HL), particularly in young females who receive radiotherapy for early-stage HL ([@b1-ol-07-04-1001]--[@b3-ol-07-04-1001]). By contrast, the incidence of ML, including HL and non-HL (NHL) as second malignancies following breast conserving surgery and radiotherapy (RT) for BC, is rare ([@b4-ol-07-04-1001],[@b5-ol-07-04-1001]).

Follicular lymphoma (FL) is classified as an NHL, amongst which FL is categorized as a low-grade ML and grows slowly. The incidence of FL is 20--30% of all ML in Europe and the USA ([@b6-ol-07-04-1001]), but in Japan it is only 10--15%, although it is increasing ([@b7-ol-07-04-1001]--[@b9-ol-07-04-1001]). NHL is rarely observed in the synchronous and metachronous presentation with BC, and the double presentation of BC and FL is even rarer; previously, only six cases, including metachronous and synchronous double presentation, have been reported in the literature ([@b10-ol-07-04-1001]--[@b15-ol-07-04-1001]). In the present study, a case of synchronous ductal carcinoma *in situ* (DCIS) of the breast and FL is reported, with a review of the literature.

Case report
===========

The current study describes the case of a 49-year-old female who had previously undergone bilateral breast augmentation with autologous fatty tissue injection in her youth. Prior to the study, the patient attended yearly breast screening appointments. In the most recent breast screening, the patient exhibited no obvious complaints and a mammography (MMG) examination was performed. In previous MMG examinations, no abnormal findings had been identified. The patient had undergone an autologous fat-tissue transplantation 10 years earlier. On palpation, a hard induration was palpated under the nipple of the right breast, and swelling of a soft lymph node (LN) was also palpated in the right axilla.

An MMG examination revealed two lesions: One consisted of a group of micro-calcifications in a \~1 cm^2^ area under the right nipple, and the other was a large crude calcification, 2.5 cm in diameter ([Fig. 1](#f1-ol-07-04-1001){ref-type="fig"}). Ultrasonography examination revealed a low echoic lesion, including micro-calcifications and a large calcified mass. The aforementioned examinations indicated DCIS and fat necrosis following autologous fat-tissue transplantation. Computed tomography (CT) examination revealed a crude calcification and a lesion enhanced by a contrast drug. In addition, bilateral axillary (Ax) and intra-abdominal para-aortic LN swelling were revealed. Positron emission tomography (PET) also demonstrated accumulations of ^18^F-fluorodeoxyglucose in the bilateral AxLNs and intra-abdominal para-aortic LNs ([Fig. 2](#f2-ol-07-04-1001){ref-type="fig"}). These findings indicated malignant lymphoma rather than metastasis from the breast DCIS.

The patient underwent excision of the large calcified mass ([Fig. 3A](#f3-ol-07-04-1001){ref-type="fig"}), a micro-calcified tumor ([Fig. 3B](#f3-ol-07-04-1001){ref-type="fig"}) and the right AxLN. The pathological diagnoses demonstrated that the large calcified mass was fat necrosis and the micro-calcified tumor was DCIS ([Fig. 4](#f4-ol-07-04-1001){ref-type="fig"}). For immunohistochemical (IHC) examination, 4-μm sections of formalin-fixed, paraffin-embedded specimens were immunostained primarily according to the labeled polymer method using Dako EnVision™ kit (Dako, Carpinteria, CA, USA), according to the manufacturer's instructions. The primary antibodies were purchased from Roche Diagnostics Japan (Tokyo, Japan) as follows: anti-estrogen receptor (ER) rabbit monoclonal antibody (mAb) (SP1), anti-progesterone receptor (PgR) rabbit mAb (1E2) and anti-human epidermal growth factor receptor II (HER2/new) rabbit mAb and from DakoCytomation (Glostrup, Denmark) as follows: anti-human cluster of differentiation (CD)20 mouse mAb, anti-CD79a mouse mAb, anti-CD10 mouse mAb, anti-B-cell lymphoma (Bcl)-2 mouse mAb and anti-Bcl-6 mouse mAb. IHC examinations revealed that the DCIS was positive for ER, PR and HER2 protein expression and was evaluated as 2+. The post-surgical stage classification was pTis pN0 M0, stage 0. The AxLN was diagnosed as FL ([Fig. 5](#f5-ol-07-04-1001){ref-type="fig"}), as IHC examinations revealed that the tumor cells were positive for CD20, CD79a, CD10 and Bcl-2 protein ([Fig. 5](#f5-ol-07-04-1001){ref-type="fig"}), but negative for Bcl-6 protein. The clinical stage was classified as stage III.

Treatment for FL was preferentially continued, as BC is a DCIS. The patient was administered combination chemotherapy with 600 mg rituximab, 1,100 mg cyclophosphamide, 2 mg vincristine and 80 mg prednisolone (R-CVP) at 3-week intervals for 6 cycles, and the clinical response was evaluated as a complete response. Subsequent to R-CVP therapy, the patient received radiotherapy (RT) to the conserved breast 25 times at 2.0 Gy. In total, RT was received 5 days a week for 5 weeks (total dose, 50 Gy). Subsequent to RT, the patient was administered a luteinizing hormone-releasing hormone agonist, leuprorelin acetate, at 3.75 mg at 4-week intervals. Two years have passed since the surgery, and the patient is disease-free. The patient provided written informed consent.

Discussion
==========

Synchronous or metachronous presentations of BC and FL are rare, and to the best of our knowledge, only six cases have previously been reported in the literature ([@b10-ol-07-04-1001]--[@b14-ol-07-04-1001]); the present study is the seventh case. Profiles of the seven cases are summarized in [Table I](#tI-ol-07-04-1001){ref-type="table"}. Of the seven cases, only one case was a metachronous presentation, and the FL occurred two and a half years after the BC. Six cases were synchronous presentations. The BCs of the seven cases included five invasive ductal carcinomas (IDC) and two DCISs; four cases had left-sided BCs and three had right-sided BCs. The surgeries included three mastectomies and four breast-conserving surgeries, and the stages were classified as stage 0 in two cases, stage I in three cases, stage IIA in one case and stage IIB in one case. ER was positive in all five cases that were fully described, and following the surgery, six cases were administered adjuvant therapies.

FL was classified as stage IA in two cases, stage III in three cases and unclear in two cases. The biopsy sites for pathological diagnosis included six AxLNs and one breast. Histological grades were described in five cases and all of them were classified as low grade or grade 1. Surface markers were studied in five cases and all of them were positive for CD20, CD10 and Bcl-2 protein. CD79a was positive in two reported cases and Bcl-6 protein was positive in the present case, but negative in another case reported. The treatment was described in five cases: The patient of the present case was administered R-CVP, while in the other studies, one patient received CVP, one received CB and dexamethasone, one received adriamycin and cyclophosphamide and the other patient received no treatment.

The double presentation of BC and ML is not so rare, however, the majority are cases of individuals, particularly young females, who exhibit BC as a secondary malignancy subsequent to RT or chemotherapy for HL ([@b1-ol-07-04-1001]--[@b3-ol-07-04-1001]). The double presentation of BC and NHL is rare and to the best of our knowledge, a total of 32 cases, including the present case, have been reported in the literature ([@b15-ol-07-04-1001]--[@b29-ol-07-04-1001]). Besides seven cases with FL, the double presentations of NHL and BC have accounted for 25 cases, including 22 synchronous and three metachronous presentations; the profiles are summarized in [Table II](#tII-ol-07-04-1001){ref-type="table"}. Among them, chronic lymphocytic leukemia/small lymphocytic lymphoma were most frequently observed in eight cases.

In the present literature review, in 25 of 32 cases (78%) of double presentation, NHLs were diagnosed by pathologically examining AxLNs. This indicated that the excisional biopsy of the AxLN is the most important factor for identifying ML presenting with BC. For IDC, there is no problem in terms of the diagnosis of ML, as a sentinel node biopsy (SNB) or Ax dissection are the standard procedures. On the other hand, for DCIS, the diagnosis of ML is not always easy, as SNB of an AxLN is not indicated as a standard procedure for DCIS. However, a previous meta-analysis of SNB in DCIS demonstrated that the estimate for the incidence of SN metastases in a patient with a pre-operative diagnosis of DCIS was 7.4% compared with 3.7% in patients with a definitive diagnosis of DCIS alone, which indicated that SNB should be considered in patients with a pre-operative diagnosis of DCIS ([@b30-ol-07-04-1001]). According to the present literature review, SNB may be indicated in cases of DCIS of the breast when the AxLNs are swelling. Furthermore, pre-operative PET/CT examination, if possible, may also be beneficial in detecting metastasis and in identifying other malignant diseases of the LN.
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![MMG revealing two lesions. As shown in the rectangle, one lesion was grouped as micro-calcifications in a \~1 cm^2^ area under the right nipple, which was classified as DCIS. Another was a large crude calcification of 2.5 cm in diameter, which was fat necrosis due to autologous transplantation of fatty tissue in the patient's youth. DCIS, ductal carcinoma *in situ*; MMG, mammography.](OL-07-04-1001-g00){#f1-ol-07-04-1001}

![PET demonstrating an accumulation of ^18^F-fluorodeoxyglucose in the bilateral AxLNs (SUVmax, 2.8) and intra-abdominal para-aortic LNs (SUVmax, 5.8). PET, positron emission tomography; Ax, bilateral axillary; LN, lymph node; SUVmax, maximum standardized uptake value.](OL-07-04-1001-g01){#f2-ol-07-04-1001}

![Macroscopic findings of surgical specimens. (A) A large calcified mass of fat necrosis. (B) A micro-calcified tumor of ductal carcinoma *in situ (*DCIS).](OL-07-04-1001-g02){#f3-ol-07-04-1001}

![Pathology and immunohistochemistry of the ductal carcinoma *in situ* (DCIS). Magnification, ×100. DCIS was positive for estrogen receptor (ER) and progesterone receptor (PgR), and human epidermal growth factor receptor II (HER2) protein expression was evaluated as 2+.](OL-07-04-1001-g03){#f4-ol-07-04-1001}

![Pathology and immunohistochemistry of FL. Magnification, ×100. Tumor cells were positive for CD20, CD79a, CD10 and Bcl-2 protein. FL, follicular lymphoma; CD, cluster of differentiation; Bcl, B cell lymphoma.](OL-07-04-1001-g04){#f5-ol-07-04-1001}

###### 

BC coexisting with FL.

                      Patient                                                                                                                                   
  ------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------
  Age, years          51                     61                     50                     58                     52                     74                     47
  Gender              Female                 Female                 Female                 Female                 Female                 Female                 Female
  Syn/meta            Metachro               Synchro                Synchro                Synchro                Synchro                Synchro                Synchro
  BC                                                                                                                                                            
   Side of Breast     R                      L                      L                      L                      R                      L                      R
   Histology          IDC                    IDC                    IDC                    DCIS                   IDC                    IDC                    DCIS
   Grade                                     2                      1                                             2                      2                      
   T                  1                      1                      1                      cis                    3                      1                      cis
   N                  0                      1                      0                      0                      0                      0                      0
   M                  0                      0                      0                      0                      0                      0                      0
   Stage              I                      IIA                    I                      0                      IIB                    I                      0
   ER                 (+)                                           (+)                                           (+)                    (+)                    (+)
   PgR                (−)                                           (+)                                           (+)                    (+)                    (+)
   HER2                                                                                                                                  (−)                    2+
   Surgery            MX                     WLE                    WLE                    MX                     MX                     WLE                    WLE
   Adjuvant therapy   FT                     RT+Chem                RT+TAM                 None                   TAM                    RT+AI                  LP
  FL                                                                                                                                                            
   Biopsy site        L-Br                   AxLN                   AxLN                   AxLN                   AxLN                   AxLN                   AxLN
   Grade              Low                                           1                      Low                                           1                      1
   Stage                                     III                    IIIA                   IA                     IA                                            III
   CD20                                      (+)                    (+)                                           (+)                    (+)                    (+)
   CD23                                      (+)                                                                                                                
   CD79a                                                            (+)                                                                                         (+)
   CD10                                      (+)                    (+)                                           (+)                    (+)                    (+)
   Bcl-2                                     (+)                    (+)                                           (+)                    (+)                    (+)
   Bcl-6                                                            (+)                                                                                         (−)
   Cyclin D1                                                        (−)                                                                                         
   Therapy            CVP                                           CB+DM                  None                   AC                                            R-CVP
  Reference           [@b10-ol-07-04-1001]   [@b11-ol-07-04-1001]   [@b12-ol-07-04-1001]   [@b12-ol-07-04-1001]   [@b13-ol-07-04-1001]   [@b14-ol-07-04-1001]   
  Year                1989                   2005                   2006                   2006                   2010                   2010                   2011

BC, breast cancer; FL, follicular lymphoma; metachro, metachronous; synchro, synchronous; R, right; L, left; Br, breast; IDC, invasive ductal carcinomas; DCIS, ductal carcinoma *in situ*; T, tumor; N, node; M, metastasis; MX, masectomy; RT, radiotherapy; FT, futraful; Chem, chemotherapy; TAM, tamoxifen; AI, aromatase inhibitor; LP, leuprorelin acetate; Ax, axillary; LN, lymph node; CD, cluster of differentiation; Bcl, B-cell lymphoma; CVP, cyclophosphamide + vincristine + predonosolone; CB + DM, chlorambucil + dexamethasone; AC, adriamycin + cyclophosphamide; R-CVP, rituxan + CVP.

###### 

Double presentation of BC and NHL.

  Case no.   Age, years   Gender   BC     NHL          Ref.     Year                                                  
  ---------- ------------ -------- ------ ------------ -------- --------- --------------- ---- ---------------------- ------
  Synchro                                                                                                             
   1         66           F        R      IDC          2A       BL        AxLN                 [@b16-ol-07-04-1001]   1990
   2         77           F        L      IDC          1        SLL       AxLN                 [@b16-ol-07-04-1001]   1990
   3         77           F        R      ILC          1        LPL       AxLN            3B   [@b17-ol-07-04-1001]   1994
   4         77           F        L      Paget+DCIS   0        BL        AxLN            1A   [@b17-ol-07-04-1001]   1994
   5         83           M        L      IDC                   LPL       AxLN            1A   [@b17-ol-07-04-1001]   1994
   6         62           F        R      IDC          3A       SLL/CLL   AxLN                 [@b18-ol-07-04-1001]   1997
   7         62           F        L      IDC          1        DLBCL     R-Br                 [@b19-ol-07-04-1001]   2002
   8         67           F        L      IDC          1        MCL       AxLN            1    [@b20-ol-07-04-1001]   2003
   9         79           F        L      IDC          2A       MZBL      AxLN                 [@b21-ol-07-04-1001]   2004
   10        53           F        L      IDC          2A       MALT      AxLN                 [@b22-ol-07-04-1001]   2006
   11        63           F        L      IDC          1        MCL       AxLN                 [@b12-ol-07-04-1001]   2006
   12        56           F        L      ILC          2A       MZBL      AxLN            4    [@b23-ol-07-04-1001]   2008
   13        57           F        Bil    IDCx2        Both 1   MZBL      AxLN                 [@b24-ol-07-04-1001]   2008
   14        69           F        R      IDC          1        DLBCL     R-Br                 [@b25-ol-07-04-1001]   2009
   15        74           F        R      IDCx2        2B       CLL/SLL   AxLN            0    [@b14-ol-07-04-1001]   2010
   16        54           F        L      IDC          2A       SLL       AxLN                 [@b14-ol-07-04-1001]   2010
   17        52           F        L      IDC                   DLBCL     Nasopharynx          [@b26-ol-07-04-1001]   2011
   18        87           F        n.d.   IDC                   CLL/SLL   AxLN                 [@b27-ol-07-04-1001]   2011
   19        69           F        n.d.   DCIS                  CLL/SLL   AxLN                 [@b27-ol-07-04-1001]   2011
   20        62           F        n.d.   IDC                   CLL/SLL   AxLN                 [@b27-ol-07-04-1001]   2011
   21        58           F        n.d.   IDC                   CLL/SLL   AxLN                 [@b27-ol-07-04-1001]   2011
   22        67           F        n.d.   IDC                   CLL/SLL   AxLN                 [@b27-ol-07-04-1001]   2011
  Metachro                                                                                                            
   1         53           F        n.d.   IDC          n.d.     LPL       Parotid gland   2A   [@b28-ol-07-04-1001]   1990
   2         55           F        L      IDC          2B       AILT      Neck LN         2    [@b29-ol-07-04-1001]   2003
   3         53           F        R      IDC          2B       LPL                            [@b15-ol-07-04-1001]   2004

BC, breast cancer; NHL, non-Hodgkin's lymphoma; R, right; L, left; Bil, bilateral; Histol, histology; Synchro, synchronous; metachro, metachronous; F, female, M, male; IDC, invasive ductal carcinoma; DCCIS, ductal carcinoma *in situ*; BL, B-cell lymphoma; SLL, small lymphocytic lymphoma; LPL, lymphoplasmacytic lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MCL, mantle-cell lymphoma; MZBL, marginal zone B-cell lymphoma; MALT, B-cell lymphoma of mucosa-associated lymphoid tissue; AILT, angioimmunoblastic T-cell lymphoma; LN, lymph node; Ax, axillary; Br, breast; n.d., no description.
